Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia by Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan

Get full text

Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study by Tae Min Kim, Nehal J. Lakhani, Jacob Soumerai, Manali Kamdar, Justin F. Gainor, Wells Messersmith, Philip Fanning, Shanhong Guan, Feng Jin, Alison Forgie, Hong I. Wan, Jaume Pons, Sophia S. Randolph, Won Seog Kim

Get full text

Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study by Dong Hyun Kim, Jee Hyun Kong, Junshik Hong, Ja Min Byun, Dong-Yeop Shin, Youngil Koh, Inho Kim, Jinny Park, Young Rok Do, Jeong-A Kim, Won Seog Kim, Ho-Jin Shin, Sung-Soo Yoon

Get full text

Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors by Yan Zhang, Andrés Cervantes, Stephane Champiat, Aurélien Marabelle, Patricia LoRusso, Jason J Luke, Robert Haddad, David J Pinato, Dejan Juric, María de Miguel, Won Seog Kim, Xiaobin Yuan, Peter J Hosein, Anupam M Desai, Yuanxin Rong

Get full text

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up by Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage

Get full text

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium by Jessy Xinyi Han, Min Jung Koh, Leora Boussi, Mark Sorial, Sean M. McCabe, Luke Peng, Shambhavi Singh, Ijeoma Julie Eche-Ugwu, Judith Gabler, Maria J. Fernandez Turizo, Caroline T. MacVicar, Aditya Garg, Alexander Disciullo, Kusha Chopra, Alexandra Lenart, Emmanuel Nwodo, Jeffrey Barnes, Min Ji Koh, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven M. Horwitz, Mwanasha Merrill, Eric Jacobsen, Martina Manni, Monica Civallero, Tetiana Skrypets, Athina Lymboussaki, Massimo Federico, Yuri Kim, Jin Seok Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Hasmukh Jain, Manju Sengar, Carrie Van Der Weyden, Henry Miles Prince, Ramzi Hamouche, Tinatin Murdashvili, Francine Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won-Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al-Mansour, Josie Ford, Maria Elena Cabrera, Amy Ku, Govind Bhagat, Helen Ma, Ahmed Sawas, Khyati Maulik Kariya, Makoto Iwasaki, Forum Bhanushali, Owen A. O’Connor, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Get full text